Valion Bio, Inc. (VBIO)
About Valion Bio, Inc.
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2024
- $780.0K
- Net income
- -$8.9M
- Total assets
- $31.6M
- Market cap
- $2.4M
Source: SEC EDGAR · updated Jun 8, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $2.4M
- Shares outstanding
- 8.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 11, 2021
Valion Bio, Inc. (VBIO) Stock Price
- Reported a net loss of $8.9M in FY2024.
- Trading 73% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Valion Bio, Inc..
Write a review
Valion Bio, Inc.: frequently asked questions
Is Valion Bio, Inc. an American company?
Valion Bio, Inc. is a US-based company headquartered in San Antonio, Texas, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Valion Bio, Inc. headquartered?
Valion Bio, Inc. is headquartered in San Antonio, Texas, United States.
Is Valion Bio, Inc. publicly traded?
Yes — Valion Bio, Inc. is a publicly traded company. Its stock trades under the ticker symbol VBIO on the NASDAQ.
What does Valion Bio, Inc. do?
Valion Bio, Inc. is an American Medical Devices company in the Health & Beauty sector.
